Petros Pharmaceuticals, Inc.: Petros Pharmaceuticals Activates Advisory Committee to Help Guide Rx-to-OTC Switch for STENDRA

Team composed of former FDA officials and key clinical and regulatory opinion leaders to help provide insight in preparation for collaboration with FDANEW YORK, NY / ACCESSWIRE / May 21, 2024 / Petros

Related Keywords

Jules Abraham ,Nasdaq ,Exchange Commission ,Advisory Committee ,Drug Administration ,Securities Exchange ,Endo Pharmaceuticals ,Petros Pharmaceuticals ,Petros Pharmaceuticals Inc ,Auxilium Pharmaceuticals ,Fady Boctor ,Chief Commercial ,Drug Facts Label ,Label Comprehension Studies ,Self Selection Studies ,Actual Use Trial ,Additional Conditions ,Nonprescription Use ,Safety Information ,Non Arteritic Ischemic Optic Neuropathy ,Erectile Dysfunction Therapies ,Prescribing Information ,Securities Act ,Securities Exchange Act ,Nasdaq Stock Market ,Financial Condition ,Ihr Portfolio ,